Treatment Horizons

Chronic Relief? A self-injectable monoclonal antibody vies to become a monotherapy by Chael Needle Anti-HIV agents currently being researched these days seem split between (1) improving regimens...

Countdown Researcher Jia Xie discusses a cutting-edge treatment in development by Dann Dulin Block HIV by using the body’s own immune cells? Is it truly possible?! Well, such...

Shock Value Research on SMYD2 shows potential to wake up the HIV reservoir by Chael Needle HIV latency—where HIV hides out in reservoirs, dormant and beyond the...

LifeGuide Two Birds, One Stone Researchers make advances with agents that can target dual points of entry by Mariel Selbovitz, MPH Drug discovery and early to mid-stage drug...

Treatment Horizons Another Kind of Morning HIV therapeutic vaccines try to come of age by Mariel Selbovitz, MPJ, and David Miller Despite over three decades of research on...

LifeGuide Blocking the First Step A silk-protein film aims to become an HIV prevention method by Chael Needle   When we think of HIV prevention in sexually active...

NAPWA helps to promote immune-based therapies by Chael Needle At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...

An independent interim review of the Strategic Timing of AntiRetroviral Treatment (START) study findings shows that initializing treatment early improves outcomes for individuals with...

As the United States Conference on AIDS (USCA 2015) will convene shortly (September 10–13) in Washington, D.C.—and its theme is “The Numbers Don’t Lie:...

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...